Marketing expenses associated with Palynziq commercial efforts and launch preparations for Roctavian resulted in 16% increase in SG&A expenses to $153.7 million.As of Mar 31, 2020, BioMarin had $1.15 billion in cash, cash equivalents and investments, compared with $1.17 billion at the end of Dec 31, 2019.2020 GuidanceBioMarin lowered its total revenue guidance by 5% due to the uncertainty surrounding the coronavirus outbreak and its potential impact on its business.On the conference call, the company announced valroxâ€™s brand name to be Roctavian.With the FDA granting priority review to the application, a decision is expected on Aug 21.